Want to see AURX full AI Analyst Report?
AURX Stock Chart & Stats
$2.00
$0.00(0.00%)
At close: 4:00 PM EST
$2.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.84 - $3.23
Previous CloseN/A
Volume8.36K
Average Volume (3M)2.99K
Market Cap
$48.41M
Enterprise Value$44.64M
Total Cash (Recent Filing)$263.83K
Total Debt (Recent Filing)$1.10M
Price to Earnings (P/E)―
Beta0.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,408,730
10 Day Avg. Volume655
30 Day Avg. Volume2,988
Financial Highlights & Ratios
PEG Ratio-10.00
Price to Book (P/B)-97.44
Price to Sales (P/S)28.13
P/FCF Ratio-81.78
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue10.80
Enterprise Value/Gross Profit16.51
Enterprise Value/Ebitda-21.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line GrowthSustained revenue growth to roughly $4.1M TTM and reported growth of ~24.7% indicates expanding commercial traction for the company’s wound‑care offerings. Durable top‑line momentum improves scale economics potential and provides a platform to leverage fixed costs toward breakeven over the next several quarters.
High Gross MarginsA ~65% gross margin reflects a structurally profitable product mix for autologous cell therapy-based wound treatments. High product-level margins provide a durable cushion for operating leverage as revenue grows, improving the likelihood that incremental sales will meaningfully reduce overall losses over a multi‑quarter horizon.
Access To Committed FinancingThe company demonstrated the ability to secure structured, lender‑backed commitments totaling up to $2.0M, including near‑term funding already drawn. This shows access to liquidity and investor/lender support that can sustain operations and execution over coming months while management works toward improving cash flow.
Bears Say
Negative Shareholders' EquityNegative shareholders’ equity signals cumulative losses have eroded the capital base and materially weakens solvency. This structural balance‑sheet impairment limits financing flexibility, increases creditor scrutiny, and raises the risk of restrictive covenants or more dilutive financing if operational improvement is delayed.
Persistent Cash BurnOngoing negative operating and free cash flow near the mid‑single‑million annual level indicates the business still requires external funding to maintain operations. Continued cash burn is a durable risk driver that can force frequent capital raises or costly financing, impeding long‑term planning and reinvestment.
Warrant Dilution / Equity OverhangThe financing structure relies heavily on warrants and issuances tied to the loan facility, creating a material prospective equity overhang. This structural dilution risk can impair existing equity holders, raise long‑term cost of capital, and complicate future fundraising or strategic transactions as warrants convert or discourage new investors.
Nuo Therapeutics News
AURX FAQ
What was Nuo Therapeutics’s price range in the past 12 months?
Nuo Therapeutics lowest stock price was $0.84 and its highest was $3.23 in the past 12 months.
What is Nuo Therapeutics’s market cap?
Nuo Therapeutics’s market cap is $48.41M.
When is Nuo Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nuo Therapeutics’s earnings last quarter?
Currently, no data Available
Is Nuo Therapeutics overvalued?
According to Wall Street analysts Nuo Therapeutics’s price is currently Overvalued.
Does Nuo Therapeutics pay dividends?
Nuo Therapeutics does not currently pay dividends.
What is Nuo Therapeutics’s EPS estimate?
Nuo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuo Therapeutics have?
Nuo Therapeutics has 48,408,730 shares outstanding.
What happened to Nuo Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuo Therapeutics?
Currently, no hedge funds are holding shares in AURX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuo Therapeutics
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.